Gemini Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GMTX research report →
Price Chart
About the company
Gemini Therapeutics, Inc. operates as a clinical-stage precision medicine enterprise, dedicated to crafting various therapeutic solutions for age-related macular degeneration (AMD) with a genetic foundation. Its flagship investigational product, GEM103, is a recombinant human complement factor H protein engineered to address dry AMD in patients.
- IPO
- 2020
- Employees
- 24
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on GMTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $24.70
- 52W Low
- $1.35
- 50D MA
- $16.65
- 200D MA
- $15.80
- Beta
- 0.00
- RSI (14)
- 27
- Avg Volume
- 22.36K
No earnings-call transcripts are available for GMTX yet.
- Free Float
- 16.4%
- Shares Outstanding
- 18.88M
- Float Shares
- 3.09M
of shares held by institutions
44 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Foresite Capital Opportunity Management V, LLC | 2.44M | 0 |
| Amalgamated Financial Corp. | 2.90K | ▲ 2.90K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 10, 24 | Bitterman Kevin | sell | 20,000 |
| Jan 10, 24 | Atlas Venture Fund X, L.P. | sell | 30,000 |
| Jan 10, 24 | Atlas Venture Fund X, L.P. | sell | 20,000 |
| Dec 29, 23 | Quisel John D | other | 2,700 |
| Dec 29, 23 | Quisel John D | other | 2,700 |
| Dec 27, 23 | Bryce Joanne | other | 3,000 |
| Dec 27, 23 | Bryce Joanne | other | 3,000 |
| Dec 18, 23 | ORBIMED ADVISORS LLC | other | 1,724 |
| Dec 18, 23 | ORBIMED ADVISORS LLC | other | 1,724 |
| Dec 18, 23 | ORBIMED ADVISORS LLC | sell | 1,724 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GMTX coverage
Recent articles, reports, and earnings notes.
No research on GMTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GMTX report →Gemini Therapeutics Announces ASCO 2026 Analyses Supporting Aldoxorubicin's Tumor-Targeted Delivery and Cardiac-Safety Profile
businesswire.com · May 27
FDA reversals leave investors worrying about the fates of other experimental drugs
cnbc.com · Mar 6
iBio (NASDAQ:IBIO) versus Gemini Therapeutics (NASDAQ:GMTX) Critical Review
defenseworld.net · Mar 2
Gemini Therapeutics (NASDAQ:GMTX) Shares Down 2.6% – What’s Next?
defenseworld.net · Jan 30
7 Short-Squeeze Stocks for Bold Contrarians to Consider
investorplace.com · Nov 21
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY
prnewswire.com · Sep 26
GEMINI THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. – GMTX
headlinesoftoday.com · Sep 21
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ
prnewswire.com · Aug 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.